Background: COVID19 in patients affected by lymphoma represents an important challenge because of the higher mortality rate compared to the general population, due to the underlying disease and the immunosuppressive treatments that make them a particularly vulnerable population. Anti-SARS-CoV-2 monoclonal antibodies (anti-S MoAbs) appear promising in this setting.
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study / Assanto, GIOVANNI MANFREDI; DI ROCCO, Alice; Malfona, Francesco; Capriata, Marcello; DEL GIUDICE, Ilaria; Petrucci, Luigi; Girardi, Paola; Maria D'elia, Gianna; Martelli, Maurizio; Gentile, Giuseppe; Micozzi, Alessandra; Pulsoni, Alessandro. - In: BLOOD. - ISSN 0006-4971. - (2022). [10.1182/blood-2022-164544]
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study
Giovanni Manfredi Assanto
;Alice Di Rocco;Francesco Malfona;Marcello Capriata;Ilaria Del Giudice;Paola Girardi;Maurizio Martelli;Giuseppe Gentile;Alessandra Micozzi;Alessandro Pulsoni
2022
Abstract
Background: COVID19 in patients affected by lymphoma represents an important challenge because of the higher mortality rate compared to the general population, due to the underlying disease and the immunosuppressive treatments that make them a particularly vulnerable population. Anti-SARS-CoV-2 monoclonal antibodies (anti-S MoAbs) appear promising in this setting.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
